首页> 外文期刊>Nucleic Acids Research >A rapid biosensor chip assay for measuring of telomerase activity using surface plasmon resonance - art. no. e4
【24h】

A rapid biosensor chip assay for measuring of telomerase activity using surface plasmon resonance - art. no. e4

机译:一种利用表面等离振子共振测量端粒酶活性的快速生物传感器芯片测定-art。没有。 e4

获取原文
获取原文并翻译 | 示例
           

摘要

Considerable interest has been focused on telomerase because of its potential use in assays for cancer diagnosis, and for anti-telomerase drugs as a strategy for cancer chemotherapy. A number of assays based on the polymerase chain reaction (PCR) have been developed for evaluation of telomerase activity. To overcome the disadvantages of the conventional telomerase assay [telomeric repeat amplification protocol (TRAP)] related to PCR artifacts and troublesome post-PCR procedures, we have developed a telomeric repeat elongation (TRE) assay which directly measures telomerase activity as the telomeric elongation rate by biosensor technology using surface plasmon resonance (SPR). 5'-Biotinylated oligomers containing telomeric repeats were immobilized on streptavidin-pretreated dextran sensor surfaces in situ using the BIACORE apparatus. Subsequently, the oligomers associated with the telomerase extracts were elongated in the BIACORE apparatus. The rate of TRE was calculated by measuring the SPR signals. We examined elongation rates by the TRE assay in 18 cancer and three normal human fibroblast cell lines, and 12 human primary carcinomas and matching normal tissues. The elongation rates increased in a concentration- and time-dependent manner. Those of cancer cells were two to 10 times higher than fibroblast cell lines and normal tissues. Telomerase activities and its inhibitory effects of anti-telomerase agents as measured by both the TRE and TRAP assays showed a good correlation. Our assay allows precise quantitative comparison of a wide range of human cells from somatic cells to carcinoma cells. TRE assay is suitable for practical use in the assessment of telomerase activity in preclinical and clinical trials of telomerase-based therapies, because of its reproducibility, rapidity and simplicity.
机译:由于端粒酶潜在地用于癌症诊断检测和抗端粒酶药物作为癌症化学治疗的策略,因此人们对端粒酶的关注已引起广泛关注。已经开发了许多基于聚合酶链反应(PCR)的检测方法来评估端粒酶活性。为克服传统端粒酶测定[端粒重复扩增协议(TRAP)]与PCR伪影和麻烦的PCR后程序有关的缺点,我们开发了一种端粒重复延伸(TRE)测定法,可直接测量端粒酶活性作为端粒延伸率通过使用表面等离子体共振(SPR)的生物传感器技术实现。使用BIACORE设备将含有端粒重复序列的5'-生物素化的寡聚体原位固定在链霉亲和素预处理的葡聚糖传感器表面上。随后,在BIACORE设备中将与端粒酶提取物相关的寡聚物拉长。通过测量SPR信号来计算TRE的速率。我们通过TRE分析检测了18种癌症和3种正常人成纤维细胞系以及12种人类原发性癌和匹配的正常组织中的伸长率。伸长率以浓度和时间相关的方式增加。癌细胞的表达量是成纤维细胞系和正常组织的2至10倍。通过TRE和TRAP分析测定的端粒酶活性及其对端粒酶抑制剂的抑制作用显示出良好的相关性。我们的测定方法可以对从人体细胞到癌细胞的各种人类细胞进行精确的定量比较。 TRE测定法可重现,快速且简便,因此适合在端粒酶疗法的临床前和临床试验中评估端粒酶活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号